Skip to main content

Advertisement

Table 1 Baseline characteristics in patients with advanced hepatobiliary cancers (n = 80)

From: Significance of serum ferritin as a prognostic factor in advanced hepatobiliary cancer patients treated with Korean medicine: a retrospective cohort study

Variables Values Total (n) Percent (%)
Clinicopathological factors
 Age (years) < 65 / ≥65 50/30 62.5/37.5
 Gender Female / Male 27/53 33.8/66.3
 ECOG-PS 0 / 1 / 2 14/52/14 17.5/65.0/17.5
 BMI (kg/m2) < 23 / ≥23 44/36 55.0/45.0
 Tumor Type HCC / BTC / cHCC-CC 33/44/3 41.3/55.0/3.8
 Previous anticancer therapy No / Yes 25/55 31.3/68.8
 Prior surgery No / Yes 44/36 55.0/45.0
 Prior chemotherapy No / 1st line / 2nd line / ≥3rd line 47/17/7/9 58.8/21.3/8.8/11/3
 Prior radiotherapy No / Yes 66/14 82.5/17.5
 Prior TACE No / 1 / 2 / ≥3 60/3/5/12 75.0/3.8/6.3/15.0
 Prior RFA No / Yes 71/9 88.8/11.3
Laboratory factors
 Ferritin (ng/mL) Lowa / Highb 45/35 56.3/43.8
 Hb (g/dL) Lowc / Highd 50/30 62.5/37.5
 Total bilirubin (mg/dL) ≤1.2 / > 1.2 64/16 80.0/20.0
 AST (IU/L) < 40 / ≥40 37/43 46.3/53.8
 ALT (IU/L) < 40 / ≥40 46/34 57.5/42.5
 γ-GT (IU/L) ≤66 / > 66 25/55 31.3/68.8
 PT INR ≤1.16 / > 1.16 57/23 71.3/28.8
 Albumin (g/dL) < 3.5 / ≥3.5 13/67 16.3/83.8
 WBC (×103/μL) < 10.0 / ≥10.0 70/10 87.5/12.5
 CRP (mg/L) < 10.0 / ≥10.0 40/40 50.0/50.0
  1. COG-PS Eastern cooperative oncology group performance status, BMI body mass index, TACE transarterial chemoembolization, RFA radiofrequency ablation, Hb hemoglobin, AST aspartate aminotransferase, ALT alanine aminotransferase, rGT gamma-glutamyl transpeptidase, PT INR prothrombin time international normalized ratio, WBC white blood cell, CRP c-reactive protein, HCC hepatocellular carcinoma, BTC biliary tract cancers, cHCC-CC combined hepatocellular-cholangiocarcinoma
  2. a female≤150 male≤200, b female> 150 male> 200, c female < 12.0 male < 13.0, d female ≥12.0 male ≥13.0